NRx Pharmaceuticals, Inc. $NRXP Shares Bought by Anson Funds Management LP

Anson Funds Management LP lifted its stake in shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) by 26.2% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 2,025,104 shares of the company’s stock after acquiring an additional 420,129 shares during the quarter. NRx Pharmaceuticals makes up about 0.6% of Anson Funds Management LP’s investment portfolio, making the stock its 26th biggest position. Anson Funds Management LP owned 0.10% of NRx Pharmaceuticals worth $6,683,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the stock. Ethos Financial Group LLC purchased a new position in shares of NRx Pharmaceuticals in the 3rd quarter valued at $39,000. One Wealth Management Investment & Advisory Services LLC lifted its position in NRx Pharmaceuticals by 86.1% in the third quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock valued at $92,000 after acquiring an additional 12,950 shares during the last quarter. Two Sigma Investments LP boosted its stake in NRx Pharmaceuticals by 66.4% in the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock valued at $173,000 after acquiring an additional 20,880 shares in the last quarter. Geode Capital Management LLC boosted its stake in NRx Pharmaceuticals by 27.9% in the second quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock valued at $562,000 after acquiring an additional 37,598 shares in the last quarter. Finally, AdvisorShares Investments LLC grew its holdings in shares of NRx Pharmaceuticals by 29.7% during the third quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock worth $1,129,000 after purchasing an additional 78,339 shares during the last quarter. Institutional investors and hedge funds own 4.27% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Ascendiant Capital Markets reiterated a “buy” rating and set a $48.00 target price (up from $47.00) on shares of NRx Pharmaceuticals in a research report on Friday, January 2nd. Weiss Ratings restated a “sell (e+)” rating on shares of NRx Pharmaceuticals in a research note on Monday, December 29th. Zacks Research raised NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, March 2nd. Wall Street Zen upgraded NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, November 23rd. Finally, BTIG Research reissued a “buy” rating and issued a $25.00 price objective on shares of NRx Pharmaceuticals in a report on Wednesday, February 18th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $38.00.

NRx Pharmaceuticals Price Performance

NRXP opened at $1.86 on Friday. NRx Pharmaceuticals, Inc. has a 12 month low of $1.58 and a 12 month high of $3.84. The stock has a market capitalization of $59.28 million, a P/E ratio of -0.79 and a beta of 1.97. The business has a 50 day simple moving average of $2.00 and a 200-day simple moving average of $2.47.

NRx Pharmaceuticals Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.